Evaluation of Cost-Effectiveness of Live Oral Pentavalent Reassortant Rotavirus Vaccine Introduction in Ghana
This article, published in Vaccine, estimates the cost-effectiveness of introducing the rotavirus vaccine RotaTeq® in Ghana. The authors estimated the average costs of treating children with diarrhea in the Ashanti region of Ghana as inpatients and outpatients, and then used these results, along with data from rotavirus surveillance studies and recent rotavirus vaccine efficacy evaluation, to estimate cost-effectiveness. Based on their results, the authors concluded that RotaTeq® vaccination for children younger than the age of five in Ghana would be a highly cost-effective public health intervention. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Abbott C, Tiede B, Armah G, Mahmoud A
Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Abbott C, Tiede B, Armah G, Mahmoud A. Evaluation of Cost-Effectiveness of Live Oral Pentavalent Reassortant Rotavirus Vaccine Introduction in Ghana. Vaccine. 2012;30(15):2582-2587.